EU and US could reach trade deal this weekend - Reuters
On Monday, Cantor Fitzgerald analysts maintained an Overweight rating on Cerus stock (NASDAQ:CERS) and affirmed a price target of $4.00, representing significant upside potential from the current price of $1.27. According to InvestingPro data, analyst targets range from $4.00 to $5.00, suggesting strong confidence in the company’s potential. This decision follows the announcement of regulatory approvals for Cerus’ INT200 illumination device in France and Switzerland, which are significant markets for platelets.
Cerus received CE Mark approval for the INT200 device in March. The device is designed to improve workflow and ergonomics in blood centers with its compact vertical setup, touchscreen interface, and smart scanning technology. The company plans to transition its existing INT100 devices in the Europe, Middle East, and Africa (EMEA) region to the INT200 model over the next three years.
In addition to the current approvals, Cerus is preparing to submit further regulatory applications. This includes a planned premarket approval (PMA) submission to the U.S. Food and Drug Administration (FDA) in 2026.
The continued regulatory progress and strategic plans for device upgrades underscore Cerus’ commitment to enhancing operations in blood centers. The reiterated Overweight rating and price target reflect confidence in Cerus’ growth potential in the platelet market.
In other recent news, Cerus Corporation reported its Q1 2025 earnings, showing a net loss of $7.7 million, or $0.04 per share, which met analyst expectations. However, the company’s revenue of $48.9 million slightly missed the forecasted $49.61 million, despite a 13% year-over-year increase in product revenue. North American revenues surged by 22%, while EMEA saw a slight decline, contributing to the revenue miss. Cerus also received regulatory approval for its INT200 blood safety device from French and Swiss authorities, enhancing the existing INTERCEPT Blood System. The company plans to transition to the INT200 platform in EMEA over the next three years, with further regulatory submissions, including a PMA to the FDA, planned for 2026. Additionally, Cerus is set to present new data on its INTERCEPT Blood System at the ISBT Congress, highlighting its efficacy in various blood components. Analyst firms, including TD Cowen and Cantor Fitzgerald, have shown interest in Cerus’ geographic expansion and the potential impact of new regulatory approvals on future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.